Negative effect of serotonin-norepinephrine reuptake inhibitor therapy on rat bone tissue after orchidectomy
| Autor: | Helena Zivna, Iva Karesova, Martin Mzik, Sona Fekete, Pavel Zivny, Ladislava Pavlikova, Vladimir Palicka, Julius Simko |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
musculoskeletal diseases
Genetic Markers medicine.medical_specialty Bone Morphogenetic Protein 2 Bone tissue Bone and Bones Collagen Type I Bone remodeling chemistry.chemical_compound Absorptiometry Photon N-terminal telopeptide Osteoprotegerin Bone Density Internal medicine medicine Animals Humans Femur Rats Wistar Serotonin and Noradrenaline Reuptake Inhibitors Pharmacology Lumbar Vertebrae Tibia Osteoid business.industry Venlafaxine Hydrochloride Alkaline Phosphatase Peptide Fragments Biomechanical Phenomena Diaphysis medicine.anatomical_structure Endocrinology chemistry Bone Morphogenetic Proteins Sclerostin Cortical bone Bone Remodeling business Peptides Orchiectomy Biomarkers Procollagen |
| Zdroj: | European journal of pharmacology. 761 |
| ISSN: | 1879-0712 |
| Popis: | Our goal was to determine if venlafaxine has a negative effect on bone metabolism. Rats were divided into three groups. The sham-operated control group (SHAM), the control group after orchidectomy (ORX), and the experimental group after orchidectomy received venlafaxine (VEN ORX) in standard laboratory diet (SLD) for 12 weeks. Bone mineral content (BMC) was measured by dual energy X-ray absorptiometry (DXA). Bone marker concentrations of carboxy-terminal cross-linking telopeptide of type I collagen (CTX-I), osteoprotegerin (OPG), amino-terminal propeptide of procollagen type I (P1NP), bone alkaline phosphatase (BALP), sclerostin and bone morphogenetic protein 2 (BMP-2) were examined in bone homogenate. The femurs were used for biomechanical testing. Compared to the ORX group we found lower BMD in the diaphysis area of the femur in the VEN ORX group, suggesting a preferential effect on cortical bone. Of the bone metabolism markers, there was significant decrease (ORX control group versus VEN ORX experimental group) in BALP levels and increase in sclerostin and CTX-I levels, suggesting a decrease in osteoid synthesis and increased bone resorption. The results suggest that the prolonged use of venlafaxine may have a negative effect on bone metabolism. Further studies are warranted to establish whether venlafaxine may have a clinically significant adverse effect on bone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect